Loading...
Rivaroxaban, an oral factor Xa inhibitor that is not yet FDA approved, is one of several new potential substitutes for warfarin. In this report, researchers present the results of two industry-sponsored trials that involved rivaroxaban.
In one study, 3449 patients with acute symptomatic proximal deep venous thrombosis (DVT) — but without clinically apparent pulmonary embolism — were randomized to receive either oral rivaroxaban or standard therapy (enoxaparin followed by warfarin); treatment duration was 3 to 12 months. The incidence of recurrent venous thromboembolism was slightly lower with rivaroxaban than with standard therapy (2.1% vs. 3.0%), and the incidence of bleeding was the same in both groups.
In another study, 1197 patients who h…